Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.
29 citations,
January 2019 in “Journal of the European Academy of Dermatology and Venereology” Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.
Belimumab effectively controls SLE disease activity and reduces steroid use.
April 2023 in “Research Square (Research Square)” Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.
Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.
44 citations,
October 2020 in “Arthritis Care & Research” Choosing the right tools is crucial for accurately measuring lupus activity and damage.
15 citations,
March 2021 in “Rheumatology and Immunology Research” Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.
11 citations,
September 2022 in “The Journal of Rheumatology” Skin problems are common in lupus patients and should be treated early to prevent worsening.
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
71 citations,
May 2019 in “Rheumatology” Tph cells are linked to the severity of systemic lupus erythematosus.
40 citations,
October 2012 in “Journal of the American Academy of Dermatology” CLASI is a valid tool for assessing skin activity and damage in lupus patients.
1 citations,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
Psychosis can be an early sign of neuropsychiatric lupus, treatable with tailored medication.
39 citations,
September 2017 in “The Open Rheumatology Journal” Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.
34 citations,
June 2007 in “The Journal of Dermatology” Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.
30 citations,
October 2013 in “Lupus” Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.
15 citations,
December 2011 in “Journal of the European Academy of Dermatology and Venereology” Hair loss in systemic lupus erythematosus patients is unique and improves with treatment.
1 citations,
November 2015 in “Journal of Evolution of Medical and Dental Sciences” Certain skin symptoms can help detect and manage systemic lupus.
June 2024 in “Research Square (Research Square)” Absence of skin rash and low complement C3 levels increase the risk of lupus nephritis.
Hair chemicals don't cause SLE but may increase skin issues in those with SLE.
December 2023 in “Revista de la Facultad de Ciencias Médicas (Quito)” Fever and rash can be early signs of lupus.
Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.
April 2019 in “Abstracts” Adding colchicine stopped the girl's recurring heart issues caused by lupus.
Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.
March 2018 in “Suez Canal University Medical Journal” NKG2D gene polymorphism doesn't affect SLE risk but may influence symptoms like rash and hair loss.
213 citations,
June 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
87 citations,
July 2012 in “Expert Review of Clinical Immunology” Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.
52 citations,
March 2007 in “Dermatologic Therapy” The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.
46 citations,
June 2018 in “American Journal of Clinical Dermatology” Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.